शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

ANTHEMBSEANTHEM BIOSCIENCES LTD· Pharmaceuticals & BiotechnologyLowNeutral
Announced Wed, 28 Oct, 2026 · 12:42 IST

Board meeting to approve September quarter and half-year results

EBITDA margin expansionResults View source PDFExplain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.3%Reaction day
₹835.10
prior close
₹831.15
announcement price
In-mkt
timing
Nifty Midcap 150market+0.3%-0.6% vs market
Biotechnology peers, median of 5sector+0.5%-0.8% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.8 pts less than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.0
10m
+0.2
15m
+0.1
30m
+0.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.3+0.3-0.6+0.5-0.8
Next day
-0.6+1.2-1.8+2.2-2.8
2d
-0.6+0.2-0.8-0.2-0.4
3d
-0.6+1.5-2.1+7.3-8.0
4d
+2.6+2.5+0.1+4.6-2.0
5d
+6.5+4.1+2.4+6.6-0.1
1w
+9.6pendingpending+7.8+1.8
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Midcap 150Sector · Biotechnology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board will meet on November 3, 2026, to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The share trading window remains closed until 48 hours after results are declared.

Likely market impact

This is only a meeting notice. No financial figures or audit developments were disclosed, so the likely share-price impact is unclear.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹594.0 Cr₹550.0 Cr+8.0%
Operating profit₹237.5 Cr₹181.4 Cr+30.9%
Profit after tax₹211.5 Cr₹173.4 Cr+21.9%
EBITDA margin45.7%39.6%+6.1 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.